Clairvoyant Therapeutics announced that the first clinical trial participant in Finland enrolled in CLA-PSY 201 has received their first dose of the drug along with motivational enhancement therapy. CLA-PSY 201 is a randomized, multi-site phase 2 b trial that explores psilocybin therapy as a treatment for alcohol use disorder.
The first trial site in Finland is overseen by CLA-PSY 201 principal investigator, Dr. Hannu Alho. Dr. Alho is a professor at the Finnish National Institute for Health and Welfare THL and chief doctor at Addiktum Oy, a Finnish company founded and owned by drug addiction treatment specialists and a research center for the study.
The trial is now underway on two continents because of this milestone. Damian Kettlewell, CEO and co-founder, Clairvoyant, said we are excited to randomize our first patient in Europe. The Clairvoyant team is pleased that six clinical trial sites are recruiting patients in Canada and Europe. An increasing number of dosing visits are scheduled for March and subsequent months. We are looking forward to opening eight additional sites in the coming quarter to expedite patient recruitment, as well as have a clear line of sight on an interim data readout in Q 3 2023 and full recruitment by Q 4 2023. We appreciate the continued support of our experienced clinical, regulatory and financial team and partners. Clairvoyant hopes to be the first company to secure market authorization for psilocybin as a therapeutic product in Europe, the UK and Canada. The interim data readout will be published later this year.
This is the place where money is raised, M&A starts, and companies meet key partners. On April 11 - 12 at the Fontainebleau Miami Beach Hotel in Florida.